Impact of different models based on blood samples and images for bone marrow dosimetry after
177Lu-DOTATATE
Bone marrow
Dosimetry
Internal radiotherapy
SPECT/CT
Journal
EJNMMI physics
ISSN: 2197-7364
Titre abrégé: EJNMMI Phys
Pays: Germany
ID NLM: 101658952
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
28
04
2023
accepted:
15
01
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
epublish
Résumé
Peptide receptor radionuclide therapy with The bone marrow dose was calculated for 131 treatments with the blood-based method and for 17 with the image-based method. In the former, the median absorbed dose was 15.3, 20.5 and 28.3 mGy/GBq with the mono-, bi- and tri-exponential model, respectively. With the image-based method, the median absorbed dose was 63.9, 41.9 and 60.8 with the mono-, bi- and tri-exponential model, respectively. Blood samples after 24h post-injection did not evidence any change in the absorbed bone marrow dose with the bi-exponential model. On the contrary, the 6-day post-injection timepoint was more informative with the image-based model. This study confirms that the estimated bone marrow dose is significantly lower with the blood-based method than with the image-based method. The blood-based method with a bi-exponential model proved particularly useful, without the need for blood samples after 24h post-injection. Nevertheless, this blood-based method is based on an assumption that needs to be more validated. The important difference between the two methods does not allow to determine the optimal one to estimate the true absorbed dose and further studies are necessary to compare with biological effects.
Sections du résumé
BACKGROUND
BACKGROUND
Peptide receptor radionuclide therapy with
RESULTS
RESULTS
The bone marrow dose was calculated for 131 treatments with the blood-based method and for 17 with the image-based method. In the former, the median absorbed dose was 15.3, 20.5 and 28.3 mGy/GBq with the mono-, bi- and tri-exponential model, respectively. With the image-based method, the median absorbed dose was 63.9, 41.9 and 60.8 with the mono-, bi- and tri-exponential model, respectively. Blood samples after 24h post-injection did not evidence any change in the absorbed bone marrow dose with the bi-exponential model. On the contrary, the 6-day post-injection timepoint was more informative with the image-based model.
CONCLUSION
CONCLUSIONS
This study confirms that the estimated bone marrow dose is significantly lower with the blood-based method than with the image-based method. The blood-based method with a bi-exponential model proved particularly useful, without the need for blood samples after 24h post-injection. Nevertheless, this blood-based method is based on an assumption that needs to be more validated. The important difference between the two methods does not allow to determine the optimal one to estimate the true absorbed dose and further studies are necessary to compare with biological effects.
Identifiants
pubmed: 38564043
doi: 10.1186/s40658-024-00615-5
pii: 10.1186/s40658-024-00615-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Informations de copyright
© 2024. The Author(s).
Références
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.
doi: 10.1007/s00259-011-1902-1
pubmed: 21892623
Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6:1086–92.
doi: 10.1001/jamaoncol.2020.0078
pubmed: 32297906
Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.
doi: 10.1007/s00259-014-2893-5
pubmed: 25273832
Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.
doi: 10.2967/jnumed.112.119347
pubmed: 24009272
Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022 [cited 2022 Apr 6]; Available from: https://doi.org/10.1007/s00259-022-05727-7 .
Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, et al. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60:1406–13.
doi: 10.2967/jnumed.118.225235
pubmed: 30902877
pmcid: 6785794
Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970–88.
doi: 10.1007/s00259-018-3945-z
pubmed: 29497803
pmcid: 5915504
Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138.
doi: 10.1007/s00259-009-1072-6
pubmed: 19247653
pmcid: 2691529
Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405.
doi: 10.1007/s00259-008-0761-x
pubmed: 18491092
Page ER. Impact of 3D image based dosimetry on treatment planning in Peptide Receptor Radionuclide Therapy (PRRT). 381.
Kwekkeboom DJ, Willem H. Bakker, Peter P. M. Kooij, Mark W. Konijnenberg, Ananth Srinivasan, Jack L. Erion, et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;1319–25.
Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC | cancer biotherapy and radiopharmaceuticals. Cancer Biotherapy & Radiopharmaceuticals. 2007 [cited 2022 Nov 22]; https://doi.org/10.1089/cbr.2006.325
Jackson PA, Beauregard J-M, Hofman MS, Kron T, Hogg A, Hicks RJ. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Med Phys. 2013;40:112503.
doi: 10.1118/1.4824318
pubmed: 24320462
Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.
doi: 10.2967/jnumed.112.107524
pubmed: 23223392
Denoyer D, Lobachevsky P, Jackson P, Thompson M, Martin OA, Hicks RJ. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J Nucl Med. 2015;56:505–11.
doi: 10.2967/jnumed.114.145581
pubmed: 25722453
Bergsma H, Konijnenberg MW, Kam BLR, Teunissen JJM, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43:453–63.
doi: 10.1007/s00259-015-3193-4
pubmed: 26419852
Svensson J, Rydén T, Hagmarker L, Hemmingsson J, Wängberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016 [cited 2017 Jan 25];3. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031567/
Del Prete M, Buteau F-A, Beauregard J-M. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490–500.
doi: 10.1007/s00259-017-3688-2
pubmed: 28361189
Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J, et al. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0, Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res. 2018;8:76.
doi: 10.1186/s13550-018-0427-z
pubmed: 30076556
pmcid: 6081875
Del Prete M, Buteau F-A, Arsenault F, Saighi N, Bouchard L-O, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728–42.
doi: 10.1007/s00259-018-4209-7
pubmed: 30506283
Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget J-P, et al. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Res. 2018;8:103.
doi: 10.1186/s13550-018-0459-4
pubmed: 30498938
pmcid: 6265360
Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, et al. A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med. 2018;56:41–9.
doi: 10.1016/j.ejmp.2018.11.001
pubmed: 30527088
Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J, et al. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). Br J Radiol. 2018;91:20170172.
doi: 10.1259/bjr.20170172
pubmed: 30028180
pmcid: 6475937
Chicheportiche A, Artoul F, Schwartz A, Grozinsky-Glasberg S, Meirovitz A, Gross DJ, et al. Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT). EJNMMI Phys. 2018;5:10.
doi: 10.1186/s40658-018-0211-1
pubmed: 29916115
pmcid: 6006002
Hallqvist A, Svensson J, Hagmarker L, Marin I, Rydén T, Beauregard J-M, et al. Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: a dosimetry rationale. Biomedicines. 2021;9:1570.
doi: 10.3390/biomedicines9111570
pubmed: 34829796
pmcid: 8615768
Carter LM, Ramos JCO, Kesner AL. Personalized dosimetry of 177Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomed Phys Eng Express. 2021;7:057002.
doi: 10.1088/2057-1976/ac1550
Vergnaud L, Giraudet A-L, Moreau A, Salvadori J, Imperiale A, Baudier T, et al. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for 177Lu-DOTATAE therapy. EJNMMI Phys. 2022;9:37.
doi: 10.1186/s40658-022-00462-2
pubmed: 35575946
pmcid: 9110613
Lambert M, Dierickx L, Brillouet S, Courbon F, Chatelut E. Comparison of two types of amino acid solutions on 177Lu-dotatate pharmacokinetics and pharmacodynamics in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Curr Radiopharm. 2022;15:164–72.
doi: 10.2174/1874471015666211228123525
pubmed: 35105299
Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, et al. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys. 2020;7:36.
doi: 10.1186/s40658-020-00308-9
pubmed: 32488632
pmcid: 7266908
Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Gouill SL, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116:1093–100.
doi: 10.1002/cncr.24797
pubmed: 20127958
Glass HI, de Garreta AC. The quantitative limitations of exponential curve fitting. Phys Med Biol. 1971;16:119.
doi: 10.1088/0031-9155/16/1/312
pubmed: 5579745
Beykan, S et al. Patient-specific dosimetry of 177Lu-dotatate peptide receptor radionuclide therapy with high activities. Eur J Nucl Med Mol Imaging 2018;45(Suppl 1):S33 OP-081. 2018.
Hemmingsson J, Svensson J, Hallqvist A, Smits K, Johanson V, Bernhardt P. Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment. J Nucl Med [Internet]. 2023 [cited 2023 Sep 22]; Available from: https://jnm.snmjournals.org/content/early/2023/06/08/jnumed.123.265484
Lubberink M, Wilking H, Öst A, Ilan E, Sandström M, Andersson C, et al. In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61:1337–40.
doi: 10.2967/jnumed.119.237818
pubmed: 32005767
pmcid: 7456166
Walrand S, Jamar F. Renal and red marrow dosimetry in peptide receptor radionuclide therapy: 20 years of history and ahead. Int J Mol Sci. 2021;22:8326.
doi: 10.3390/ijms22158326
pubmed: 34361092
pmcid: 8347073
van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Löwenberg B, et al. Somatostatin and the immune and haematopoetic system: a review. Eur J Clin Invest. 1994;24:91–9.
doi: 10.1111/j.1365-2362.1994.tb00972.x
pubmed: 7911420
Derlin T, Bogdanova N, Ohlendorf F, Ramachandran D, Werner RA, Ross TL, et al. Assessment of γ-H2AX and 53BP1 foci in peripheral blood lymphocytes to predict subclinical hematotoxicity and response in somatostatin receptor-targeted radionuclide therapy for advanced gastroenteropancreatic neuroendocrine tumors. Cancers. 2021;13:1516.
doi: 10.3390/cancers13071516
pubmed: 33806081
pmcid: 8036952
Eberlein U, Nowak C, Bluemel C, Buck AK, Werner RA, Scherthan H, et al. DNA damage in blood lymphocytes in patients after 177Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1739–49.
doi: 10.1007/s00259-015-3083-9
pubmed: 26048612
pmcid: 4554740
Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88.
doi: 10.1007/s00259-014-2824-5
pubmed: 24915892